Posted by Michael Wonder on 06 Dec 2022
Emergent BioSolutions announces US FDA acceptance and priority review of supplemental new drug application for over the counter Narcan (naloxone hydrochloride) nasal spray
6 December 2022 - Emergent’s supplemental new drug application is the first prescription to over the counter switch application in history to be granted priority review by the FDA.
Today, Emergent BioSolutions announced that the US FDA has accepted for review its supplemental new drug application for Narcan (naloxone hydrochloride) nasal spray, as an over the counter emergency treatment for known or suspected opioid overdose.
